



PRESS RELEASE

Published 08-05-2019

Decisions from Annual General Meeting of Asarina Pharma, 8 May 2019

(Stockholm May 8, 2019) **On 8 May 2019, the Annual General Meeting ("AGM") of Asarina Pharma AB (publ) was held in Stockholm. Read below for a summary of the decisions made.**

Dividend

In accordance with the board's proposal, the AGM resolved that no dividend is to be paid for the financial year 2018.

Discharge from liability

The board of directors and the CEO were discharged from liability for the financial year 2018.

Board of directors

Paul de Potocki, Marianne Kock, Miroslav Reljanovic and André Ulmann were re-elected as board members and Mathieu Simon and Vidar Wendel-Hansen were elected as new board members. It was noted that Thierry Laugel and Ola Flink had declined to be re-elected, and therefore resigned from the board of directors. Paul de Potocki was also re-elected as chairman of the board of directors.

It was resolved that remuneration to the board of directors will amount to SEK 500,000 for the chairman of the board and SEK 200,000 to every other independent board member.

Auditor

Ernst & Young Aktiebolag was re-elected as auditor, with the authorised public accountant Stefan Andersson-Berglund as principle auditor. It was resolved that remuneration to the auditor will be according to approved invoicing.

Authorisation for the board of directors to resolve on new issues of shares, share warrants or convertibles

In accordance with the board's proposal, the board of directors was authorised to decide, on one or several occasions before the next AGM, on new issue of shares, share warrants or convertibles with or without deviation from the shareholders' preferential rights. The Board of Directors undertook to only use the authorization as regards issues with deviation from the shareholders' preferential rights as regards shares and not to a greater extent than the total number of shares issued by virtue of the authorisation amounting to a maximum of 15 per cent of the number of shares outstanding at the time of the notice to the AGM 2019. The Board of Directors furthermore undertook to ensure that any new issues of shares resolved on by virtue of the authorisation and with deviation from the shareholders' preferential rights are being made on market terms (which means, inter alia, that the terms shall comply

with the recommendation on Private Placements issued by the Swedish Corporate Governance Board on 21 November 2014).

For more information, please contact:

Peter Nordkild, CEO, Asarina Pharma AB

Phone: +45 25 47 16 46

E-mail: peter.nordkild@asarinapharma.com

Jakob Dynnes Hansen, CFO, Asarina Pharma AB

Phone: +45 5132 3698

E-mail: jakob.dynnes@asarinapharma.com

Certified Adviser

Erik Penser Bank AB

Box 7405,

103 91 Stockholm

Phone: +46 8-463 83 00

Mail: certifiedadviser@penser.se

About Asarina Pharma

We are a Swedish biotech company developing Sepranolone, the world's first dedicated treatment for premenstrual dysphoric disorder (PMDD) and other menstrual-related conditions. Our product pipeline is built on over 40 years' research into menstrual-related disorders like PMDD and menstrual migraine. With our new family of GAMSAs (GABA_A Modulating Steroid Antagonists), we aim to deliver a new generation of efficacious and safe drugs for still widely untreated conditions, thereby becoming a leading Women's Health company. Find more information at

<http://www.asarinapharma.com>